Aberrant circulating levels of purinergic signaling markers are associated with several key aspects of peripheral atherosclerosis and thrombosis

Circulation Research

Volumn 116, Issue 7, 2015, Pages 1206-1215

  Jalkanen, Juho ^a   Yegutkin, Gennady G ^c   Hollmén, Maija ^c   Aalto, Kristiina ^c   Kiviniemi, Tuomas ^b   Salomaa, Veikko ^d   Jalkanen, Sirpa ^c   Hakovirta, Harri ^a  

^a Department of Vascular Surgery ^*  (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Adenosine; Adenosine diphosphate; Adenosine triphosphate; Atherosclerosis; Receptors, purinergic P1; Smoking; Thrombosis

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; BIOLOGICAL MARKER; CD39 ANTIGEN; CHOLESTEROL; CREATININE; GLUCOSE; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; WARFARIN; ALKALINE PHOSPHATASE; APYRASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEUKOCYTE ANTIGEN; NT5E PROTEIN, HUMAN; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DYSLIPIDEMIA; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; GROUPS BY AGE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SMOKING; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; VERY ELDERLY; ADVERSE EFFECTS; AGE; ANOXIA; ARTIFACT; ATHEROSCLEROSIS; BIOLOGICAL MODEL; BLOOD; CHRONIC DISEASE; COMORBIDITY; COMPARATIVE STUDY; DRUG UTILIZATION; FINLAND; PERIPHERAL ARTERIAL DISEASE; RISK FACTOR; SECOND MESSENGER; THROMBOPHILIA;

5'-NUCLEOTIDASE; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANOXIA; ANTIGENS, CD; APYRASE; ARTIFACTS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CHRONIC DISEASE; COMORBIDITY; DISEASE PROGRESSION; DRUG UTILIZATION; FEMALE; FINLAND; GPI-LINKED PROTEINS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; MALE; MIDDLE AGED; MODELS, CARDIOVASCULAR; PERIPHERAL ARTERIAL DISEASE; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RISK FACTORS; SECOND MESSENGER SYSTEMS; SMOKING; THROMBOPHILIA;

EID: 84930708023     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.305715     Document Type: Article

References (43)

1. Weber C, Noels H, Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011; 17: 1410-1422. doi: 10.1038/nm.2538.
2. Hansson GK, Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695. doi: 10.1056/NEJMra043430.
3. Libby P, Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32: 2045-2051. doi: 10.1161/ATVBAHA.108.179705.
4. Colgan SP, Eltzschig HK, Eckle T, Thompson LF, Physiological roles for ecto-5'-nucleotidase (CD73). Purinergic Signal 2006; 2: 351-360. doi: 10.1007/s11302-005-5302-5.
5. Grünewald JK, Ridley AJ, CD73 represses pro-inflammatory responses in human endothelial cells. J Inflamm (Lond) 2010 7 10. doi: 10.1186/1476-9255-7-10.
6. Antonioli L, Pacher P, Vizi ES, Haskó G, CD39 and CD73 in immunity and inflammation. Trends Mol Med 2013; 19: 355-367. doi: 10.1016/j.molmed.2013.03.005.
7. Eltzschig HK, Sitkovsky MV, Robson SC, Purinergic signaling during inflammation. N Engl J Med 2012; 367: 2322-2333. doi: 10.1056/NEJMra1205750.
8. Zernecke A, Bidzhekov K, Ozüyaman B, Fraemohs L, Liehn EA, Lüscher-Firzlaff JM, Lüscher B, Schrader J, Weber C, CD73/ecto-5'-nucleotidase protects against vascular inflammation and neointima formation. Circulation 2006; 113: 2120-2127. doi: 10.1161/CIRCULATIONAHA.105.595249.
9. Buchheiser A, Ebner A, Burghoff S, Ding Z, Romio M, Viethen C, Lindecke A, Köhrer K, Fischer JW, Schrader J, Inactivation of CD73 promotes atherogenesis in apolipoprotein E-deficient mice. Cardiovasc Res 2011; 92: 338-347. doi: 10.1093/cvr/cvr218.
10. Lecka J, Bloch-Boguslawska E, Molski S, Komoszynski M, Extracellular purine metabolism in blood vessels (Part II): activity of ecto-enzymes in blood vessels of patients with abdominal aortic aneurysm. Clin Appl Thromb Hemost 2010; 16: 650-657. doi: 10.1177/1076029609354329.
11. St Hilaire C, Ziegler SG, Markello TC, NT5E mutations and arterial calcifications. N Engl J Med 2011; 364: 432-442. doi:10.1056/NEJMoa0912923.
12. Gordon JL, Extracellular ATP: effects, sources and fate. Biochem J 1986 233 309 319
13. Zimmermann H, Zebisch M, Sträter N, Cellular function and molecular structure of ecto-nucleotidases. Purinergic Signal 2012; 8: 437-502. doi: 10.1007/s11302-012-9309-4.
14. Robson SC, Wu Y, Sun X, Knosalla C, Dwyer K, Enjyoji K, Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation. Semin Thromb Hemost 2005; 31: 217-233. doi: 10.1055/s-2005-869527.
15. Huttinger ZM, Milks MW, Nickoli MS, Aurand WL, Long LC, Wheeler DG, Dwyer KM, d'Apice AJ, Robson SC, Cowan PJ, Gumina RJ, Ectonucleotide triphosphate diphosphohydrolase-1 (CD39) mediates resistance to occlusive arterial thrombus formation after vascular injury in mice. Am J Pathol 2012; 181: 322-333. doi: 10.1016/j.ajpath.2012.03.024.
16. Yegutkin GG, Wieringa B, Robson SC, Jalkanen S, Metabolism of circulating ADP in the bloodstream is mediated via integrated actions of soluble adenylate kinase-1 and NTPDase1/CD39 activities. FASEB J 2012; 26: 3875-3883. doi: 10.1096/fj.12-205658.
17. Thompson LF, Eltzschig HK, Ibla JC, Van De Wiele CJ, Resta R, Morote-Garcia JC, Colgan SP, Crucial role for ecto-5'-nucleotidase (CD73) in vascular leakage during hypoxia. J Exp Med 2004; 200: 1395-1405. doi: 10.1084/jem.20040915.
18. Thompson LF, Takedachi M, Ebisuno Y, Tanaka T, Miyasaka M, Mills JH, Bynoe MS, Regulation of leukocyte migration across endothelial barriers by ECTO-5'-nucleotidase-generated adenosine. Nucleosides Nucleotides Nucleic Acids 2008; 27: 755-760. doi: 10.1080/15257770802145678.
19. Vartiainen E, Jousilahti P, Alfthan G, Sundvall J, Pietinen P, Puska P, Cardiovascular risk factor changes in Finland, 1972-1997. Int J Epidemiol 2000 29 49 56
20. Helenius M, Jalkanen S, Yegutkin G, Enzyme-coupled assays for simultaneous detection of nanomolar ATP, ADP, AMP, adenosine, inosine and pyrophosphate concentrations in extracellular fluids. Biochim Biophys Acta 2012; 1823: 1967-1975. doi: 10.1016/j.bbamcr.2012.08.001.
21. Yegutkin GG, Samburski SS, Mortensen SP, Jalkanen S, González-Alonso J, Intravascular ADP and soluble nucleotidases contribute to acute prothrombotic state during vigorous exercise in humans. J Physiol 2007; 579: 553-564. doi: 10.1113/jphysiol.2006.119453.
22. Niemelä J, Ifergan I, Yegutkin GG, Jalkanen S, Prat A, Airas L, IFN-beta regulates CD73 and adenosine expression at the blood-brain barrier. Eur J Immunol 2008; 38: 2718-2726. doi: 10.1002/eji.200838437.
23. Bellingan G, Maksimow M, Howell DC, The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study. Lancet Respir Med 2014; 2: 98-107. doi:10.1016/S2213-2600(13)70259-5.
24. Mercier N, Kiviniemi TO, Saraste A, Miiluniemi M, Silvola J, Jalkanen S, Yegutkin GG, Impaired ATP-induced coronary blood flow and diminished aortic NTPDase activity precede lesion formation in apolipoprotein E-deficient mice. Am J Pathol 2012; 180: 419-428. doi: 10.1016/j.ajpath.2011.10.002.
25. Burnstock G, Ralevic V, Purinergic signaling and blood vessels in health and disease. Pharmacol Rev 2014; 66: 102-192. doi: 10.1124/pr.113.008029.
26. Zhou Y, Murthy JN, Zeng D, Belardinelli L, Blackburn MR, Alterations in adenosine metabolism and signaling in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. PLoS One 2010 5 e9224. doi:10.1371/journal.pone.0009224.
27. Esther CR Jr, Lazaar AL, Bordonali E, Qaqish B, Boucher RC, Elevated airway purines in COPD. Chest 2011; 140: 954-960. doi: 10.1378/chest.10-2471.
28. Eltzschig HK, Ibla JC, Furuta GT, Leonard MO, Jacobson KA, Enjyoji K, Robson SC, Colgan SP, Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J Exp Med 2003; 198: 783-796. doi: 10.1084/jem.20030891.
29. Yegutkin GG, Helenius M, Kaczmarek E, Burns N, Jalkanen S, Stenmark K, Gerasimovskaya EV, Chronic hypoxia impairs extracellular nucleotide metabolism and barrier function in pulmonary artery vasa vasorum endothelial cells. Angiogenesis 2011; 14: 503-513. doi: 10.1007/s10456-011-9234-0.
30. Banz Y, Beldi G, Wu Y, Atkinson B, Usheva A, Robson SC, CD39 is incorporated into plasma microparticles where it maintains functional properties and impacts endothelial activation. Br J Haematol 2008; 142: 627-637. doi: 10.1111/j.1365-2141.2008.07230.x.
31. Diehm N, Shang A, Silvestro A, Do DD, Dick F, Schmidli J, Mahler F, Baumgartner I, Association of cardiovascular risk factors with pattern of lower limb atherosclerosis in 2659 patients undergoing angioplasty. Eur J Vasc Endovasc Surg 2006; 31: 59-63. doi: 10.1016/j.ejvs.2005.09.006.
32. Buergler JM, Maliszewski CR, Broekman MJ, Kaluza GL, Schulz DG, Marcus AJ, Raizner AE, Kleiman NS, Ali NM, Effects of SolCD39, a novel inhibitor of platelet aggregation, on platelet deposition and aggregation after PTCA in a porcine model. J Thromb Thrombolysis 2005; 19: 115-122. doi: 10.1007/s11239-005-1381-y.
33. Willigendael EM, Teijink JA, Bartelink ML, Peters RJ, Büller HR, Prins MH, Smoking and the patency of lower extremity bypass grafts: a meta-analysis. J Vasc Surg 2005; 42: 67-74. doi: 10.1016/j.jvs.2005.03.024.
34. Dong A, Caicedo J, Han SG, Mueller P, Saha S, Smyth SS, Gairola CG, Enhanced platelet reactivity and thrombosis in Apoe-/- mice exposed to cigarette smoke is attenuated by P2Y12 antagonism. Thromb Res 2010 126 e312 e317. doi: 10.1016/j.thromres.2010.03.010.
35. Rollini F, Franchi F, Cho JR, Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic study. J Cardiovasc Transl Res 2014; 7: 53-63. doi:10.1007/s12265-013-9535-3.
36. Gurbel PA, Bliden KP, Logan DK, Kereiakes DJ, Lasseter KC, White A, Angiolillo DJ, Nolin TD, Maa JF, Bailey WL, Jakubowski JA, Ojeh CK, Jeong YH, Tantry US, Baker BA, The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. J Am Coll Cardiol 2013; 62: 505-512. doi: 10.1016/j.jacc.2013.03.037.
37. Desai NR, Mega JL, Jiang S, Cannon CP, Sabatine MS, Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol 2009; 53: 1273-1278. doi: 10.1016/j.jacc.2008.12.044.
38. Gagne JJ, Bykov K, Choudhry NK, Toomey TJ, Connolly JG, Avorn J, Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison. BMJ 2013 347 f5307
39. Kaneider NC, Egger P, Dunzendorfer S, Noris P, Balduini CL, Gritti D, Ricevuti G, Wiedermann CJ, Reversal of thrombin-induced deactivation of CD39/ATPDase in endothelial cells by HMG-CoA reductase inhibition: effects on Rho-GTPase and adenosine nucleotide metabolism. Arterioscler Thromb Vasc Biol 2002 22 894 900
40. Kiviniemi TO, Yegutkin GG, Toikka JO, Paul S, Aittokallio T, Janatuinen T, Knuuti J, Rönnemaa T, Koskenvuo JW, Hartiala JJ, Jalkanen S, Raitakari OT, Pravastatin-induced improvement in coronary reactivity and circulating ATP and ADP levels in young adults with type 1 diabetes. Front Physiol 2012 3 338. doi: 10.3389/fphys.2012.00338.
41. Ledoux S, Lovastatin enhances ecto-5'-nucleotidase activity and cell surface expression in endothelial cells: implication of Rho-family GTPases. Circ Res 2002; 90: 420-427. doi:10.1161/hh0402.105668.
42. Molnar MZ, Kalantar-Zadeh K, Lott EH, Lu JL, Malakauskas SM, Ma JZ, Quarles DL, Kovesdy CP, Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease. J Am Coll Cardiol 2014; 63: 650-658. doi: 10.1016/j.jacc.2013.10.050.
43. Smink PA, Miao Y, Eijkemans MJ, Bakker SJ, Raz I, Parving HH, Hoekman J, Grobbee DE, de Zeeuw D, Lambers Heerspink HJ, The importance of short-term off-target effects in estimating the long-term renal and cardiovascular protection of angiotensin receptor blockers. Clin Pharmacol Ther 2014; 95: 208-215. doi: 10.1038/clpt.2013.191.